Du Bois A, Rochon J, Lamparter C, Pfisterer J
Dept. Gynaecology & Gynaecologic Oncology, HSK Wiesbaden, Germany.
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):183-91. doi: 10.1111/j.1525-1438.2005.15202.x.
The purpose of this study was to evaluate the pattern and quality of care for ovarian cancer in Germany and analyze prognostic factors with emphasis on characteristics of treating institutions, hospital volume, and participation in clinical trials. This study utilized national survey including patients with histologically proven invasive epithelial ovarian cancer diagnosed in the third quarter of 2001 including descriptive analysis of pattern of surgical care and systemic treatment in early (FIGO I-IIA) and advanced (FIGO IIB-IV) ovarian cancer and both univariate and multivariate analysis of prognostic factors. One third of all patients diagnosed in the third quarter of 2001 in Germany, 476 patients, were included. Standard care according to German guidelines was provided to only 35.5% of patients with early ovarian cancer. Recommended chemotherapy was given to 78% in advanced disease. Multivariate analysis showed advanced stage, poor performance status, comorbidity, ascites, and treatment in an institution not participating in cooperative studies to be associated with inferior survival. Non-participation was associated with an 82% increase of risk (HR = 1.82; 95% CI, 1.27-2.61; P= 0.001). Hospital volume did not affect treatment outcome. Adherence to treatment guidelines showed remarkable variety among German hospitals, indicating options and need for improvement. Selecting an institution that participates in cooperative trials might be an option for individual patients seizing the chance for better quality of care even when individual factors might hamper enrollment in a study.
本研究的目的是评估德国卵巢癌的治疗模式和护理质量,并分析预后因素,重点关注治疗机构的特征、医院规模以及参与临床试验的情况。本研究采用了一项全国性调查,纳入了2001年第三季度确诊的组织学确诊的浸润性上皮性卵巢癌患者,包括对早期(FIGO I-IIA)和晚期(FIGO IIB-IV)卵巢癌手术护理和全身治疗模式的描述性分析,以及对预后因素的单变量和多变量分析。纳入了2001年第三季度在德国确诊的所有患者的三分之一,即476例患者。只有35.5%的早期卵巢癌患者接受了德国指南规定的标准护理。晚期疾病患者中78%接受了推荐的化疗。多变量分析显示,晚期、体能状态差、合并症、腹水以及在未参与合作研究的机构接受治疗与较差的生存率相关。未参与研究与风险增加82%相关(HR = 1.82;95% CI,1.27-2.61;P = 0.001)。医院规模并未影响治疗结果。德国各医院在遵循治疗指南方面存在显著差异,这表明存在选择空间以及改进的必要性。对于个体患者而言,即使个体因素可能阻碍其入组研究,但选择参与合作试验的机构可能是获得更高护理质量的一种选择。